Compare BLCO & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | GNTX |
|---|---|---|
| Founded | 1853 | 1974 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.0B |
| IPO Year | 2022 | 1995 |
| Metric | BLCO | GNTX |
|---|---|---|
| Price | $15.03 | $25.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | $18.45 | ★ $26.60 |
| AVG Volume (30 Days) | 404.4K | ★ 2.1M |
| Earning Date | 04-29-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | ★ $5,101,000,000.00 | $2,534,268,965.00 |
| Revenue This Year | $8.65 | $6.89 |
| Revenue Next Year | $5.59 | $4.58 |
| P/E Ratio | ★ N/A | $56.61 |
| Revenue Growth | 6.47 | ★ 9.55 |
| 52 Week Low | $11.44 | $20.48 |
| 52 Week High | $18.92 | $29.38 |
| Indicator | BLCO | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 68.39 |
| Support Level | $14.55 | $25.60 |
| Resistance Level | $15.67 | $29.06 |
| Average True Range (ATR) | 0.38 | 0.55 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 25.91 | 74.24 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.